Trial Profile
A 24-week, double-blind, parallel group, placebo and active controlled study to investigate the efficacy and safety of daily oral roflumilast taken with low dose inhaled corticosteroids in patients with chronic asthma.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Dec 2016
Price :
$35
*
At a glance
- Drugs Corticosteroids (Primary) ; Roflumilast (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Sponsors AstraZeneca
- 04 May 2012 Company (Takeda Global Research and Development Center) added as trial sponsor as reported by ClinicalTrials.gov.
- 30 Oct 2005 New trial record.